Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-20; most recent amendment 2026-02-27.
Status change: Recruiting → Active, Not Recruiting 2026-02-27
Trial Details
NCT Number NCT06895343
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 100 participants
Start Date 2025-04-03
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-02